Aaron S. Mansfield, MD


Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Aaron S. Mansfield MD, Tobias Peikert, MD


Potential Applications of Immune Checkpoint Blockade for Mesothelioma

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.

Aarti S. Bhardwaj, MD


Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Aashini Master, DO


Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Abdenour Nabid, MD


Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Abdulraheem Yacoub, MD


Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Abhinav Deol, MD


Dr Deol on the Current Limitations of CAR T-cell Therapy in R/R Myeloma

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Abigail L. Stockham, MD


The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.

Abigail S. Caudle, MD


Dr. Caudle on Upcoming Breast Cancer Trial Results

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.

Abraham Chachoua, MD


Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.

​Carmela Hoefling, RN, MSN, APN-C, AOCNP


Carmela Hoefling Discusses Effects of Malnutrition During Surgery

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.

Adam Brufsky,MD


Dr. Brufsky on Treatment Options for Male Breast Cancer

Adam M. Brufsky, MD, PhD, discusses treatment options for male patients with breast cancer.

Adam D. Cohen, MD


Dr. Cohen on the Use of CAR T-cell Therapy in Earlier Lines of Multiple Myeloma Treatment

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Adam Dicker, MD, PhD


Dr. Adam Dicker on Combination Treatments With Radiation Therapy

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the potential for radiation combinations.

Adam Feldman, MD


Dr. Feldman on Link Between Obesity and Risk for RCC

Adam S. Feldman, MD, MPH, urologist, Department of Urology, Massachusetts General Hospital, discusses the association between obesity and the risk of developing total and fatal renal cell carcinoma (RCC).

Adam H. Buchanan, MS, MPH, LGC


New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers Persist

Telehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.

Adam I. Riker, MD


Treatment Options for Patients with Stage III & IV Melanoma: Part II: Experimental treatments for stage III/IV or refractory/recurrent melanoma

Various immunotherapeutic strategies to treat advanced melanoma have been under investigation for more than a decade

Adam J. Waxman, MD, MS


Dr. Waxman on the Future of Treatment in Multiple Myeloma

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.

Adam M. Brufsky, MD


Dr. Brufsky on the Utility of Zanidatamab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the unique mechanism of action of zanidatamab and encouraging efficacy observed in patients with HER2-positive breast cancer.

Adam M. Brufsky, MD, PhD


Audience Q&A: Future Directions in Breast Cancer Care

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.